A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
Clinical Trial
[키워드] acquisition
Administered
Adult
Adults
Analysis
antibody
antiviral activity
Antiviral effect
assays
clinical evidence
concentrations
decrease
different
double-blind
Effectiveness
enrolled
exhibiting
Factors
healthy subject
Human
increase in
independent
Infected
infected children
Infection
intranasal
mechanism
mRNA
multiple logistic regression
murine model
nasal
nasal washe
nucleocapsid
number of infected
PCR
Placebo
placebo-controlled study
placebo-controlled trial
Proinflammatory cytokine
proportion
Protein
protein expression
Randomized
recipient
recipients
representing
respiratory syncytial virus
RNA
RSV
RSV infection
safety profile
saline placebo
significantly lower
siRNA
subjects
tested
therapeutic
Therapeutic approach
therapy
treat
uninfected
unique
viral culture
was measured
wild-type
[DOI] 10.1073/pnas.0912186107 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1073/pnas.0912186107 PMC 바로가기 [Article Type] Clinical Trial